ArticleArchives of dermatological research2022
Down-regulated expression of miR-582 predicts poor prognosis and facilitates melanoma progression by targeting FOXC1.
Article in Archives of dermatological research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is one of the most common malignant tumors that originate from nerve sheath melanocytes and are produced in the skin and other organs. This paper mainly studied the role of miR-582 in melanoma. The expression of miR-582 in melanoma cell lines and tissues was evaluated by real-time quantitative PCR. Kaplan-Meier curve and Cox proportional hazards model analysis were used to investigate the prognostic value of miR-582 in melanoma. Cell proliferation, invasion, and migration were analyzed using CCK-8 and transwell assays. The results showed that miR-582 was significantly decreased in melanoma cells and tissues. Downregulation of miR-582 was associated with ulceration, lymph node metastasis, TNM stage, and poor overall survival. The functional results showed that low expression of miR-582 can promote cell proliferation, migration, and invasion. FOXC1 was a direct target of miR-582. Overall, the expression of miR-582 is downregulated in melanoma tissues and cell lines. Low expression of miR-582 is associated with prognosis and progression of melanoma by targeting FOXC1. miR-582 may be a prognostic biomarker and a new therapeutic strategy for melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.